Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Restaurants get off to a quick start thanks to game-changing policies
High service charges on event ticket refunds call for further regulation
Sunday
- Subscribe
Thiopurine drugs can raise risk of cancer
Source: Agencies |
October 20, 2009, Tuesday
|
Print Edition
Print Edition
SOME treatments for inflammatory bowel disease increase the risk of infection-related cancers, French scientists said yesterday, but the benefits of the drugs still outweigh the risks.
Thiopurine drugs - immunosuppressive medicines that inhibit the body's immune system - are regularly used to treat inflammatory bowel disease, the researchers said, but can increase the risk of cancers linked to viral infections.
Laurent Beaugerie and colleagues at the Saint-Antoine hospital in Paris looked at more than 19,000 patients with inflammatory bowel disease. Around 30 percent of the patients were taking thiopurines, 14 percent had stopped taking them and 56 percent had never taken them.
Following up after almost 3 years, the researchers found 23 new cases of cancers - one of Hodgkin's lymphoma and 22 of non-Hodgkin lymphoma.
Statistical analysis showed that patients receiving thiopurines - like azathioprine produced by several generic drugmakers and by GlaxoSmithKline as Imuran - had a more than five-fold increased risk of lymphoma compared with those who had never received the drugs, the researchers said in a study published in The Lancet journal.
"The absolute cumulative risk ... in young patients receiving a 10-year course of thiopurines remains low - (less than 1 percent) - and does not undermine the positive risk-benefit ratio of these drugs," researchers wrote.
Thiopurine drugs - immunosuppressive medicines that inhibit the body's immune system - are regularly used to treat inflammatory bowel disease, the researchers said, but can increase the risk of cancers linked to viral infections.
Laurent Beaugerie and colleagues at the Saint-Antoine hospital in Paris looked at more than 19,000 patients with inflammatory bowel disease. Around 30 percent of the patients were taking thiopurines, 14 percent had stopped taking them and 56 percent had never taken them.
Following up after almost 3 years, the researchers found 23 new cases of cancers - one of Hodgkin's lymphoma and 22 of non-Hodgkin lymphoma.
Statistical analysis showed that patients receiving thiopurines - like azathioprine produced by several generic drugmakers and by GlaxoSmithKline as Imuran - had a more than five-fold increased risk of lymphoma compared with those who had never received the drugs, the researchers said in a study published in The Lancet journal.
"The absolute cumulative risk ... in young patients receiving a 10-year course of thiopurines remains low - (less than 1 percent) - and does not undermine the positive risk-benefit ratio of these drugs," researchers wrote.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
